ETON
insider transactionsEton Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-227.2K
0 buy · 227.2K sell
Net value · 30d
-$7.3M
$0 in · $7.3M out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
5
0 buy · 227.2K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
50.0K sh
Own New
-
Sell·S
Director
$1.6M
50.0K sh · $32.48
Own -100%
-
Exercise·M
Director
$189.0K
50.0K sh · $3.78
Own New
-
Sell·S
Sean Brynjelsen KEY
President & CEO
$4.8K
148 sh · $32.67
Own -0%
-
Sell·S
Sean Brynjelsen KEY
President & CEO
$3.8M
119.9K sh · $31.88
Own -13%
-
Exercise·M
Chief Business Officer
$0
7.2K sh
Own +6%
-
Exercise·M
Chief Business Officer
$0
12.5K sh
Own New
-
Sell·S
Chief Business Officer
$619.4K
19.7K sh · $31.47
Own -44%
-
Exercise·M
Chief Business Officer
$25.8K
7.2K sh · $3.58
Own +19%
-
Exercise·M
Chief Business Officer
$17.1K
12.5K sh · $1.37
Own +49%
-
Exercise·M
Chief Business Officer
$0
12.5K sh
Own New
-
Exercise·M
Chief Business Officer
$0
25.0K sh
Own New
-
Sell·S
Chief Business Officer
$1.2M
37.5K sh · $31.49
Own -60%
-
Exercise·M
Chief Business Officer
$17.2K
12.5K sh · $1.37
Own +25%
-
Exercise·M
Chief Business Officer
$34.5K
25.0K sh · $1.38
Own +99%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Jennifer Mckie Adams | Exercise M | 50.0K | $0 |
| Jun 17, 2026 | Jennifer Mckie Adams | Sell S | 50.0K | $1.6M |
| Jun 17, 2026 | Jennifer Mckie Adams | Exercise M | 50.0K | $189.0K |
| May 28, 2026 | Sean Brynjelsen KEY | Sell S | 148 | $4.8K |
| May 28, 2026 | Sean Brynjelsen KEY | Sell S | 119.9K | $3.8M |
| May 27, 2026 | David Krempa | Exercise M | 7.2K | $0 |
| May 27, 2026 | David Krempa | Exercise M | 12.5K | $0 |
| May 27, 2026 | David Krempa | Sell S | 19.7K | $619.4K |
| May 27, 2026 | David Krempa | Exercise M | 7.2K | $25.8K |
| May 27, 2026 | David Krempa | Exercise M | 12.5K | $17.1K |
| May 26, 2026 | David Krempa | Exercise M | 12.5K | $0 |
| May 26, 2026 | David Krempa | Exercise M | 25.0K | $0 |
| May 26, 2026 | David Krempa | Sell S | 37.5K | $1.2M |
| May 26, 2026 | David Krempa | Exercise M | 12.5K | $17.2K |
| May 26, 2026 | David Krempa | Exercise M | 25.0K | $34.5K |
About ETON insider trading
This page tracks insider transactions for Eton Pharmaceuticals, Inc. (ETON) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.